Galectin Therapeutics Inc. (NASDAQ: GALT) Stock Information | RedChip

Galectin Therapeutics Inc. (NASDAQ: GALT) Listen to this Section


$2.17
-0.0850 ( -3.78% ) 27.3K

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Market Data


Open


$2.17

Previous close


$2.25

Volume


27.3K

Market cap


$138.59M

Day range


$2.13 - $2.28

52 week range


$1.47 - $4.27

Insider Ownership Transactions

Total Amount Purchased: -1,589,049.00 | $ -3,440,291.09

Date Type Amount Purchased Purchaser
2024-02-07 Sale -50000.00 AMELIO GILBERT F
2024-01-16 Buy 500.00 ELDRED KARY
2024-01-02 Sale -11606.00 LEWIS JOEL
2023-12-18 Sale -12042.00 LEWIS JOEL
2023-12-01 Sale -9880.00 LEWIS JOEL
2023-11-15 Sale -10303.00 LEWIS JOEL
2023-10-31 Sale -9444.00 LEWIS JOEL
2023-10-16 Sale -10035.00 LEWIS JOEL
2023-10-02 Sale -10035.00 LEWIS JOEL
2023-09-27 Sale -1466204.00 Uihlein Richard E

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024
4 Insider transactions 1 Feb 07, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.